Kalthus Heart & Horse AB
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Kalthus Heart & Horse AB in Lund, the clinical research focus is strongly centered on cardiovascular diseases, especially atherosclerotic cardiovascular disease, heart failure, and prevention of major cardiac events. The studies are designed to test new treatments and better ways to reduce the risk of heart attack, stroke, hospitalization, and cardiovascular death.
- Prevention of major adverse cardiovascular events in people at high risk
- Treatment strategies for atherosclerotic cardiovascular disease without prior heart attack or stroke
- Therapies aimed at lowering cardiovascular risk in established disease
- Improving care for heart failure with preserved ejection fraction and related conditions
The site is also involved in research on lipid-related risk, inflammation, and long-term safety of new cardiovascular therapies, reflecting a broad effort to improve both prevention and treatment outcomes.
Nutritional and Metabolic Diseases
This research area at Kalthus Heart & Horse AB explores the link between nutritional and metabolic diseases and cardiovascular health, with particular attention to obesity, overweight, and their impact on heart failure and vascular disease. The trials aim to evaluate whether new therapies can improve cardiovascular outcomes in people with metabolic risk factors.
- Studies in people with obesity or overweight and cardiovascular disease
- Research on heart failure with preserved or mildly reduced ejection fraction linked to excess body weight
- Trials testing treatment approaches to reduce cardiovascular complications in metabolically at-risk patients
- Evaluation of therapies that may improve both heart-related and metabolic outcomes
Overall, the work here connects cardiology with metabolic health, showing a clear interest in prevention, risk reduction, and better management of patients with overlapping heart and metabolic conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 17 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1AstraZeneca AB2active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG4trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 188 other sites in Sweden
Therapeutic Area Benchmark — Sweden
Select a therapeutic area to compare against other sites in Sweden.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Sweden
Market Share
Country: Sweden
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Kalthus Heart & Horse AB
lock Showing 1 of 15 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impactof Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV) | Amgen Inc. | Phase III | Recruiting | Oct 2025 | — |
IMP list
lock Showing 1 of 17 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dapagliflozin | 3 | Unknown | 2023-11-07 | 2025-05-06 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.